Probucol
| File:Probucol.png | |
| Systematic (IUPAC) name | |
|---|---|
|
4,4'-[propane-2,2-diylbis(thio)]bis(2,6-di-tert-butylphenol) | |
| Identifiers | |
| CAS Number | 23288-49-5 |
| ATC code | C10AX02 (WHO) |
| PubChem | CID 4912 |
| Synonyms | 2,6-di-tert-butyl-4-({2-[(3,5-di-tert-butyl-4-hydroxyphenyl)sulfanyl]propan-2-yl}sulfanyl)phenol |
| Chemical data | |
| Formula | C31H48O2S2 |
| Molar mass | 516.844 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Probucol is an anti-hyperlipidemic drug[1] initially developed in the treatment of coronary artery disease.
However, clinical trials were stopped after it was found that may lower HDL in patients with a previous history of heart disease.
Probucol was initially developed in the 1970s by a chemical company to maximize airplane tire longevity.
Mechanism
Probucol lowers the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism. Additionally, probucol may inhibit cholesterol synthesis and delay cholesterol absorption [2]. Probucol is a powerful antioxidant which inhibits the oxidation of cholesterol in LDLs; this slows the formation of foam cells, which contribute to atherosclerotic plaques.
It is believed to act at ABCA1.[3]
It also lowers levels of HDL.[4]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- 2Fix
- Antioxidants
- Phenols
- Cardiovascular system drug stubs
